In a report released today, Ben Klieve from National Securities Corp maintained a Buy rating on Arcadia Biosciences (RKDA – Research Report), with a price target of $4.50. The company’s shares closed last Monday at $3.01.
According to TipRanks.com, Klieve is ranked #239 out of 7257 analysts.
Currently, the analyst consensus on Arcadia Biosciences is a Moderate Buy with an average price target of $6.25.
Arcadia Biosciences’ market cap is currently $40.49M and has a P/E ratio of -1.90. The company has a Price to Book ratio of 4.39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcadia Biosciences, Inc. is an agricultural biotechnology company which engages in the development of agricultural products for the improvement of the environment and human health. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. The company’s portfolio of agricultural productivity traits includes Nitrogen Use Efficiency, Water Use Efficiency, Drought Tolerance, Salinity Tolerance and Herbicide Tolerance. It has presence in the United States, Africa, India, the United Arab Emirates, Belgium, France and Canada. The company was founded by Eric J. Rey and John G. Sperling in 2002 and is headquartered in Davis, CA.